Mineral and bone diseases (MBD) are common in patients with chronic kidney disease who undergo kidney transplantation. The incidence, types and severity of MBD vary according to the duration of chronic kidney disease, presence of comorbid conditions and intake of certain medications. Moreover, multiple types of pathology may be responsible for MBD. After successful reversal of uremia by kidney transplantation, many bone and mineral disorders improve, while immunosuppression, other medications, and new and existing comorbidities may result in new or worsening MBD. Chronic kidney disease is also common after kidney transplantation and may impact bone and mineral disease. In this article, we reviewed the prevalence, pathophysiology, and impact of MBD on post-transplant outcomes. We also discussed the diagnostic approach; immunosuppression management and potential treatment of MBD in kidney transplant recipients.
There are conflicting data among the findings described in the various studies, but the main pathology in bone remodeling after renal transplantation consists of decreased bone formation and mineralization associated with persistent bone resorption. Likewise, the pathological defective bone formation may be a consequence of decreased osteoblastogenesis, osteoblast function, or increased osteoblast death rate.

3. Mineral bone disorders after kidney transplantation and its consequences

3.1. Fractures and Bone Mineral Density (BMD) Disturbances

It is well known that loss of bone mass occurs primarily in the first 12 months after kidney transplantation, predominantly in cortical bone. As shown by dual-energy X-ray absorptiometry (DXA), the most rapid decrease in bone mineral density (BMD) occurs in the first 6 months after transplantation, and seems to slow thereafter, possibly because of decreased use of corticosteroids. A study conducted by Rojas et al. [12] showed that osteoid thickness, osteoid volume, osteoid resorption surface, and osteoclast surface were above the normal range before transplant and remained elevated 35 days after transplantation. However, osteoblast surfaces and osteoid, which were also increased before transplantation, significantly diminished within 35 days post-transplant [12]. There was also inhibition of bone formation after transplantation, mineralization, and apoptosis, which were associated with doses of glucocorticoids [12]. It has been reported that BMD decreases to a mean of 5.5%–19.5% during the first 6 months, [13] and only 2.6%–8.2% between the 6th and 12th month after transplantation, [14]. It is only 0.4%–4.5% of the mean thereafter [15]. There is a 3.6–3.8-fold higher overall fracture risk in renal transplantation patients compared to healthy individuals, [16,17]

| Type of bone disease | Main characteristics | Potential harm effects |
|----------------------|----------------------|------------------------|
| High turnover: Hyperparathyroid | It is characterized by marked increase in bone turnover, irregularly shaped trabecules displaying numerous abnormal remodeling sites, and an unusually high number of bone cells with irregular arrangement and shape | Increased risk of fracture? Increased risk of mortality and graft loss? |
| Low turnover: Adynamic | It is characterized by reduced bone volume, and mineralization is paralleled by a decrease in bone formation. It is also characterized by presence of few osteoid seams and few osteoblasts. Osteoclast number may be low, normal, or high. | Increased cardiovascular risk/calcifications Increased risk of fracture? |
| Osteomalacia | It is characterized by accumulation of unmineralized matrix in which decrease in mineralization precedes or is more pronounced than the inhibition of collagen deposition. | Increased risk of fracture? Increased risk of mortality and graft loss? |
| Mixed renal osteodystrophy | It is primarily caused by defective mineralization with or without increased bone formation and by increased parathyroid hormone activity in bone. These features coexist to varying degrees in different patients. Bone volume is extremely variable and depends on a dominant pathogenic cause. Other features of mixed uremic osteodystrophy include increased numbers of heterogeneous remodeling sites and, typically, an increase in osteoclast number. | Increased risk of fracture? Mortality and graft loss risk? |

transplant were as follows: adynamic bone disease (n = 12); mild disease (n = 3); mixed bone disease (n = 3); and osteitis fibrosa (n = 2). Post-transplantation, most patients had adynamic bone disease (n = 11) compared to mild disease (n = 8) and osteomalacia (n = 1) [10]. However, conflicting results were observed in a different study from Germany [11]. The most frequent forms of renal osteodystrophy were osteitis fibrosa, which was observed in 14 patients (24.6%). Seven patients (12.3%) had mixed uremic osteodystrophy, 3 patients (5.3%) had adynamic renal bone disease, and 2 patients (3.5%) had osteomalacia [11]. Moreover, 13 patients (22.8%) were observed to have reduced bone mass and structural damage without typical signs of renal osteodystrophy, such as endosteal fibrosis or osteolasia, whereas normal histomorphometric parameters were observed in 5 patients (8.7%) [11].

Hence, low turnover bone disease (adynamic bone disease and osteomalacia) is the most common bone disorder in kidney transplant recipients. These patients show delayed mineralization and decreased mineral deposition rate explained by the intense decrease in PTH levels in patients with relatively mild bone disease before transplantation [6] and by the high doses of glucocorticoids [9]. Rojas et al. showed that post-transplant osteoblast surface correlated positively with PTH levels and negatively with glucocorticoid cumulative dose; consequently PTH seems to have a protective effect by preserving osteoblast survival [12]. Moreover, one study conducted by Velasquez-Forero et al. [7] primarily showed changes that were consistent with adynamic bone disease and increased deposition of iron, whereas other studies have shown persistent bone resorption as decreased bone formation and prolonged mineralization lag time [8].
and this is 30% higher during the first 3 years post transplantation compared to patients on dialysis [16]. Moreover, several publications have confirmed the heightened fracture risk after renal transplantation as compared with maintenance dialysis. Ball et al. found that 3 years after transplantation, the risk for hip fracture increased by 34% when compared with dialysis patients [16]. Patel et al. evaluated 165 transplant patients and found that 16% of patients had either vertebral deformities or a history of a low trauma fracture after transplantation [18]. A recent systematic review of 262,678 recipients showed fracture sites varied by study resulting in a highly variable incidence rate ranging from 3.3 to 99.6 fractures per 1000 person-years [19].

Similarly, the 5-year cumulative incidence for fracture varied ranging from 0.85% to 27% [19]. Ramsey-Goldman et al. found that the foot was the most common site of fracture in both premenopausal and postmenopausal women after transplantation [20]. In a retrospective study, which followed patients up to 33 years, diabetic nephropathy and age were independent predictors of fracture risk, while higher activity levels were shown to be protective factors [17]. There are additional risk factors for fracture that include female sex and having had a combined kidney–pancreas transplantation. Compared to waitlisted dialysis patients, there is a 1.34-fold greater relative risk of hip fracture associated with transplantation when compared with dialysis. There was a 1% decrement of risk per month up until 630 days after transplantation at which time the estimated risk became equal for dialysis and transplant recipients [16]. The risk of vertebral fracture is higher in renal transplant recipients; this risk is greater than their risk of lower extremity fractures [17].

3.1.1. Vitamin D and FGF-23

Low serum 25-OH-vitamin D levels are very common following kidney transplantation, both during the immediate postoperative period and in long-term graft recipients [21]. The KDIGO guidelines suggested that [22] kidney transplant patients should be assessed for the presence of vitamin D deficiency by examining circulating levels of 25-(OH) vitamin D (calcidiol), and vitamin D deficiency and insufficiency should be corrected by applying treatment strategies recommended for the general population. After kidney transplantation, the level of 1,25(OH)₂ vitamin D (calcitriol), and vitamin D deficiency and insufficiency should be corrected by applying treatment strategies recommended for the general population [23].

Immunosuppressive therapy, PTH level and residual renal function are the most important predictors of low 1,25(OH)₂ vitamin D levels [24]. Pre-transplantation PTH levels and low post-transplantation levels of FGF-23 were observed to be additional predictors of improved post-transplantation 1,25(OH)₂ vitamin D levels, although these were weaker than renal graft function [24]. However, more recently Sanchez Fructuoso showed serum FGF-23 concentrations remain increased in long-term kidney graft recipients, even in the early stages of CKD [25]. In addition, FGF-23 appears to be a strong and independent predictor of mortality in prevalent kidney transplant recipients [26].

4. What are the Contributors to MBD in Kidney Transplantation?

There are numerous contributing factors, but the main factors are as follow: (1) pre-existing renal osteodystrophy at time of renal transplantation, (2) transplantation-specific therapies, and (3) reduced GFR.

4.1. Pre-existing renal osteodystrophy prior to renal transplantation

As all patients undergoing kidney transplant suffer from chronic renal insufficiency, they all experience pre-existing MBD. Consequently, post-transplant bone disease cannot be considered as a separate entity; rather its course is influenced by changes in mineral metabolism and bone structure before the transplant. There has been a considerable change in the spectrum of osteodystrophy in dialysis patients in the past several years. There is an increment in the incidence and the prevalence of low bone turnover, particularly adynamic bone disease. It is becoming the primary type of bone alteration. A National Kidney Foundation (NKF) group studying renal osteodystrophy published a review suggesting that renal bone disease should be characterized by three histologic features: mineralization, turnover, and volume. In a survey of 544 bone biopsy samples from with CKD stage 5 patients, bone turnover was normal in only 21%, low in 52%, and high in 27% of biopsies. Three percent were found with defective mineralization [27]. Cancellous bone volume was normal in only 30%, low in 32%, and high in 38% [28].

It is important to differentiate between cortical and cancellous bone in the assessment of bone volume abnormalities. High turnover bone disease patients have mainly loss of cortical bone while patients with low bone turnover have mainly loss of cancellous bone [27]. Cortical bone provides the mechanical function of the bone, whereas cancellous bone provides the metabolic function. While abnormal metabolic activity results in the inability to maintain mineral metabolism, decreased bone strength results in fracture. The former is well known to be associated with vascular and soft tissue calcification.

Only a few studies analyzed the change of aluminum-related bone disease (ARB) after successful renal transplantation. David-Neto et al. examined 11 adult patients after transplantation [29]. ARBD remarkably improves 1 year following successful kidney transplantation [29]. The same authors showed that in 13 patients with adynamic bone disorders, no bone aluminum was detected at 12 months post-transplant in any of the 5 patients who had pre-transplant aluminum deposition [30].

4.1.1. Pre-existing CKD-MBD and post-transplant outcomes

Pre-existing renal osteodystrophy and markers of renal osteodystrophy, such as serum phosphorous, parathyroid hormone (PTH), and alkaline phosphatase are also associated with post-transplant mortality. Using a large dialysis organization (LDO) database, we found that more than 14,000 kidney transplant recipients have CKD-MBD data before transplantation. Using these data, we observed that there is a U-shaped association between serum phosphorous level and post-transplant mortality, with only high pre-transplant serum phosphorous levels demonstrating an association with a higher risk of graft loss [31]. Interestingly, there were no associations between serum PTH levels and post-transplant outcomes, while serum alkaline phosphatase showed a strong, linear association with post-transplant mortality and graft loss [32].

4.2. Effect of transplantation-specific therapies on bone

A major factor in the pathogenesis of post-transplant bone disease is post-transplant immunosuppressive therapy [33]. Glucocorticoid-induced acceleration in bone remodeling occurs during the first 6 months after transplantation [6]. A study that involved bone biopsies at 22 days and 160 days after transplantation depicted early osteoblast apoptosis and impaired osteoblastogenesis [12]. Numerous factors play a role in the etiology of glucocorticoid induced bone disorder. Steroids are toxic to osteoblasts and lead to increased osteoclast activity [34]. They also promote osteopenia and calcium loss. Other mechanisms include reduced gonadal hormone production, decreased calcium absorption from the gut, decreased insulin-like growth factor-1 production, diminished PTH sensitivity, increased osteoclastogenesis and increases in receptor activator of NF-kappa beta ligand (RANKL).

Both cyclosporine and tacrolimus have been linked to osteoporosis in clinical studies; [35,36] however, population-based studies focused on fracture risk could not establish an association between use of calcineurin inhibitors and fracture risk [17,18]. In addition, the Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but
severe side effect of cyclosporine and tacrolimus. This syndrome is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans [37]. Although mycophenolate mofetil, sirolimus, and azathioprine did not affect bone volume in rodents, a recent in vitro study suggests sirolimus might interfere with the proliferation and differentiation of osteoblasts. Furthermore, [38]

### Table 2
Summary of the most important clinical trials and observational studies in renal transplant recipients.

| Trial                        | Type of study | Intervention                                | Number of patients | Outcome                                                                 |
|------------------------------|---------------|---------------------------------------------|--------------------|-------------------------------------------------------------------------|
| Bisphosphonates              |               |                                             |                    |                                                                         |
| Jeffery et al. [66], 2003    | RCT           | Alendronate + calcium vs calcitriol and calcium | 117                | One year of treatment with alendronate or calcitriol, both with calcium supplementation, resulted in significant increases in BMD. The average lumbar BMD increased from 0.984 ± 0.140 to 0.992 ± 0.143 g/cm² with alendronate and from 1.014 ± 0.15 to 1.034 ± 0.146 g/cm² with calcitriol. BMD at the femur increased from 0.809 ± 0.092 to 0.836 ± 0.107 g/cm² with alendronate and from 0.830 ± 0.144 to 0.857 ± 0.125 g/cm² with calcitriol. |
| Schwarz et al. [48], 2004    | RCT           | Zoledronate + calcium vs placebo + Calcium  | 20                 | The early bone-sparing effect of short-term Zoledronate therapy confers no sustained benefit versus placebo at three year post-transplantation. Femoral neck bone mineral density z-scores increased statistically significantly from −1.3 (2.6) to −0.2 (3.6) in the placebo group and from −1.6 (2.9) to −1.2 (1.9) in the Zoledronate group. |
| Walsh et al. [67], 2009      | RCT           | Pamidronate + calcium + Vit D vs Calcium + Vit D | 93                 | Lumbar spine BMD was preserved in the Pamidronate group and decreased in the control group. Pamidronate protected BMD at the lumbar spine; bone mineral density increased by 2.1% in the treatment group and decreased by 5.7% in the control group at 12 months. Protection was also seen in Ward’s area of the hip and the total hip. |
| Grotz et al. [45], 2001      | RCT           | Ibandronate + calcium vs Calcium            | 72                 | BMD was preserved in the Ibandronate group and decreased in the control group. Changes of bone mineral density (ibandronate versus controls) were as follows: lumbar spine, −0.9% ± 6.1% versus −6.5% ± 5.4%; femoral neck, +0.5% ± 5.2% versus −7.7% ± 6.5%; and mid-femoral shaft, +2.7% ± 12.2% versus −4.8% ± 10.9%. |
| Torregrosa et al. [47], 2010 | RCT           | Risedronate + calcium + Vit D vs Calcium + Vit D | 101                | Ibandronate demonstrated a significant improvement of BMD in total femur, +1.3% versus −0.5% (p = 0.01) and in the ultradistal radius, +0.6% versus −1.9% (p = 0.039). Baseline and 12 months bone biopsy was done. Treatment with risedronate did not affect BMD in the overall cohort. In subgroup analyses, it tended to preserve BMD in female participants but did not significantly affect the BMD of male participants. Risedronate was associated with increased osteoid volume and trabecular thickness in male participants, however. After a 14-month period, the BMD of lumbar spine increased significantly (from 0.9 g/cm² to 0.92 g/cm², p < 0.001), whereas that of the hip and femoral neck did not. |
| Smerud et al. [51]           | RCT           | Ibandronate + calcium + calcitriol vs calcium and calcitriol | 129                | BMD was preserved in treated group. Mean T-scores L(2)–L(4) in treatment group at 1, 6, and 12 months were: (−2.22 ± 1.06; (−2.07 ± 1.25; (−2.17% ± 3.2%; 12 months: 0.32% ± 4.8 vs. 2.17% ± 4.4%). Baseline and 12 months bone biopsy was done. Treatment with risedronate did not affect BMD in the overall cohort. In subgroup analyses, it tended to preserve BMD in female participants but did not significantly affect the BMD of male participants. Risedronate was associated with increased osteoid volume and trabecular thickness in male participants, however. After a 14-month period, the BMD of lumbar spine increased significantly (from 0.9 g/cm² to 0.92 g/cm², p < 0.001), whereas that of the hip and femoral neck did not. |
| Coco et al. [50]             | RCT           | Risedronate + calcium + Calcitriol vs Calcium + Calcitriol | 42                 | In the treated group BMD increased and PTH decreased, whereas BMD decreased in control group. In the treated group, BMD was increased by 2.1%, 1.8%, and 3.2% in the lumbar spine, femoral neck, and forearm, respectively, whereas in the control group it decreased by 3.2%, 3.8%, and 1.8% at the same sites. |
| Huang et al. [68]            | Case–control  | Alendronate                                  | 76                 | Therapy with low-dose calcium supplements during 1 year, plus intermittent calcitriol for 3 months after transplantation, is safe, decreases PTH levels more rapidly, and prevents bone loss at the proximal femur; a more pronounced effect is seen in recipients with at least one at-risk allele of the VDR genotype. Treated patients preserved their BMD at the total hip significantly better than those on placebo (3 months: 0.04% ± 3.3 vs. −1.93% ± 3.2%; 12 months: 0.32% ± 4.8 vs. −2.17% ± 4.4%); significant differences were noted at the inter-trochanter, trochanter, and Ward’s triangle. Profile of urinary peptides was changed due to treatment with paricalcitol. |
| Nowacka-Cieciura et al. [44], 2006 | Observational | Alendronate/Risedronate vs drug free           | 66                 | Vitamin D metabolites and vitamin D receptor activators                                                                 |
| El-Agroudy et al. [69], 2003 | RCT           | Alfalcaldiol vs placebo                       | 40                 | Vitamin D metabolites and vitamin D receptor activators                                                                 |
| Torres et al. [55], 2004     | RCT           | Calcium + Calcitriol vs Calcium               | 86                 | Sermendy et al. [51]                                                                                                   |
| Perez et al. [57], 2010      | RCT           | Paricalcitol vs drug free                     | 42                 | Calcimimetics                                                                                                        |
| Lopez et al. [70], 2009      | Observational | Cinacalcet vs drug free                       | 29                 | Vitamin D metabolites and vitamin D receptor activators                                                                 |
| Cho et al. [71], 2010        | Observational | Cinacalcet vs drug free                       | 23                 | Calcimimetics                                                                                                        |
| Copley et al. [72], 2010     | Observational | Cinacalcet vs drug free                       | 41                 | Calcimimetics                                                                                                        |
| Schwarz et al. [73], 2011    | Observational | Cinacalcet vs drug free                       | 58                 | Calcimimetics                                                                                                        |

M.Z. Molnar et al. / Transplantation Reviews 28 (2014) 56–62
everolimus reduced cancellous bone loss in ovarectomized rats by decreasing osteoclast-mediated bone resorption [39].

4.3. The effects of decreased GFR after renal transplantation

Patients who are between CKD stages 3 and 5 post-transplantation are at increased risk for the development of hyperparathyroidism [40]. There was a negative correlation between intact PTH and estimated GFR in a study, which examined more than 900, transplant patients (\( \rho = -0.289, p < 0.001 \)) [40]. Additionally, high PTH values correlated well with bone loss at the hip area [41].

5. Therapy of MBD in kidney transplant recipients

There are no randomized controlled trials in transplant recipients examining bone-specific therapies on patient-level outcomes such as mortality or fractures. Moreover, there are insufficient data to recommend bone-specific-therapies within the first year of kidney transplantation. In Table 2 we show the major clinical trials and observational studies in renal transplant recipients. Several potential treatment options are as follows:

I. Glucocorticosteroid avoidance or withdrawal

One study found beneficial effects on BMD after early tapering of prednisolone [42]. The rationale for minimizing corticosteroid use relates to its established risks of osteoporosis, avascular necrosis and other side effects.

II. Bisphosphonates

There are four studies that used multiple doses of bisphosphonates (pamidronate) during the early months after renal transplantation. Prevention of bone loss occurred even after the treatment was discontinued [43]. All of these studies showed the administration of pamidronate prevented bone loss in the short period after transplantation. The studies also showed that most of the patients already had or developed de novo low turnover bone disease [43]. When other bisphosphonates were administered, similar results were found [44–48]. In comparison to vitamin D therapy, administration of bisphosphonate significantly improved the bone mineral density specially at the femoral neck and lumbar spine in kidney transplant recipients [49].

Bone biopsy was not used for diagnostic purposes in most of these trials. However, Coco et al. published a recent study in which they performed baseline and 12 month post-transplant bone biopsies after randomly assigning 42 new living-donor kidney recipients to either 35 mg of risedronate weekly or placebo for 12 months. Treatment with risedronate did not affect BMD in the overall cohort of the study [50]. In subgroup analyses, risedronate preserved BMD in females, but did not significantly affect BMD in male participants. Risedronate was associated with increased trabecular thickness and osteoid volume in male participants. Moreover, there was no evidence for the development of adynamic bone disease [50].

Recently, Smerud et al. performed a double-blinded, placebo-controlled trial of 129 renal transplant recipients with early stable renal function [51]. Patients were randomized to receive intravenous ibandronate 3 mg or intravenous placebo every 3 months for 12 months in addition to oral calcitriol 0.25 µg/day and calcium 500 mg twice a day. BMD was assessed at baseline, 10 weeks and 12 months after transplantation, and biochemical markers of bone turnover were measured. The primary endpoint was relative change in BMD [51]. BMD at the lumbar spine from baseline to 12 months was not different (+1.5% for ibandronate versus +0.5% for placebo). Ibandronate demonstrated a significant improvement of BMD in total femur (+1.3% versus −0.5%) and in the ultradistal radius (+0.6% versus −1.9%) [51]. In addition, ibandronate suppressed biomarkers of bone turnover. Calcium, calcitriol supplementation and ibandronate showed an excellent efficacy and safety profile [51]. After this study, Brandenburg and Floege highlighted some potential limitations [52]. There are definitively concerns about the use of bisphosphonates, particularly given the unresolved issues of renal safety, the unknown effects on fracture rates, and the potential exacerbation or induction of adynamic bone disease [52]. We agree [53] with Brandenburg and Floege’s [52] opinion that bisphosphonate therapy should be limited to patients who have a particularly high fracture risk and, ideally, adynamic bone disease should be excluded via bone biopsy prior to the administration of bisphosphonate therapy in kidney transplant recipients. An individualized approach is necessary for the prevention of post-transplant bone loss [53].

III. Vitamin D analogs and vitamin D receptor activators

Josephson et al. showed in a controlled, blinded study that kidney transplant recipients who were given calcium and calcitriol had less bone loss specifically in the lumbar spine and increased BMD in the distal radius compared with transplant patients given calcium alone or placebo [54]. There was no hypercalcaemia or deterioration of kidney function in patients given calcium and calcitriol. Unfortunately, there was no evaluation of fracture rates in these studies [54]. Therapy with low-dose calcium supplements over the course of 1 year, plus intermittent calcitriol for 3 months after transplantation is safe, decreases PTH levels more rapidly, and prevents bone loss at the proximal femur. Torres et al. also showed similar results [55]. Compared to placebo, calcidiol and oral calcium increased BMD at the lumbar spine and femoral neck [56]. Paricalcitol, a selective vitamin D receptor activator, is indicated in the prevention and treatment of secondary hyperparathyroidism. The profile of urinary peptide changes occurred due to treatment with paricalcitol as shown by preliminary results of this randomized controlled trial, [57] however, no study was published to assess administration of paricalcitol and the risk of bone fracture, BMD or outcomes. Hence, the treatment of calcitriol significantly improves the bone mineral density at femoral neck and lumbar spine without significantly increasing the risk of hypercalcaemia [49].

IV. Calcimimetics

Some post-transplant trials showed that cinacalcet successfully reduced elevated serum calcium and PTH levels with no adverse effects on renal function. A favorable effect of cinacalcet on BMD in renal transplant patients was reported by a few small studies [58].

V. Other treatments

Teriparatide, also known as recombinant human PTH, is another therapeutic agent that has been studied in kidney transplantation. In one study, it was administered to kidney transplant patients for 6 months; although shown to be safe, it did not alter BMD in the lumbar spine or distal radius compared with the placebo group [59]. However, BMD at the femoral neck remained unchanged in those given teriparatide, compared with a decrease in the placebo group. In addition, there was no significant difference in fractures, PTH levels, vitamin D levels, kidney function, bone histology or serologic bone markers between the two groups after 6 months [59].

5.1. Our personal approach

In our practice the management of bone and mineral disorders in kidney transplantation is divided into perioperative phase and post-operative long-term follow-up care. The perioperative phase focuses on the correction of calcium and phosphorus disarrays that are common, [60–63] treatment of hyperparathyroidism based on serum PTH and alkaline phosphatase and correction of other fluid and electrolyte problems including hyponatremia, which may be
associated to bone disorders and higher fracture rates [64]. The management strategies include the use of electrolyte and mineral supplements, diuretic therapy, Vitamin D supplement [65] and in some cases calcimetics, especially if PTH levels remain elevated. During the long-term follow up, we often follow the conventional guidelines of CKD care according and is accordance with the CKD staging. Because Vitamin D deficiency is common in kidney transplant recipients, we routinely check 25-(OH) Vitamin D level and correct the deficiency as indicated. We do not routinely check for bone density and perform bone biopsy very rarely. However, we prescribe bisphosphonate as needed and as described in this review paper.

We reserve parathyroidectomy in patients with persistently severe hyperparathyroidism after the first year post-transplant after the trial of calcimetics.

6. Conclusions

Bone disease after kidney transplantation is characterized mainly by loss of bone volume and the presence of mineralization problems, which result in low turnover bone disease in most of these patients. There are many contributing factors but the three main factors are: pre-existing renal osteodystrophy at time of renal transplantation, transplantation-specific therapies and reduced renal function. At this time, there are no well-established therapeutic approaches that provide bone anabolic effects in renal transplant recipients. Vitamin D and bisphosphonates can be used for the treatment of MBD after transplantation; however, since the most frequent abnormality after transplantation is adynamic bone disease, bone biopsy should be considered before the administration of bisphosphonates.

Acknowledgment

The authors thank for Dr. Isidro B Salusky for providing the images for Fig. 1.

Dr. Kalantar-Zadeh has received grants and/or honoraria from Abbott, Amgen, DaVita, Fresenius-Kabi, Genzyme, Otsuka, and Shire. Drs. Molnar, Naser, Rhe and Bunnappadist report no conflicts of interest.

References

[1] Hruska KA, Teitelbaum SL. Renal osteodystrophy: the new frontier. N Engl J Med 1995;333:166-74 [Epub 1995/07/20].

[2] Wang M, Herz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1–84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995;26:836-44 [Epub 1995/11/01].

[3] Bonomini V, Feletti C, Di Felice A, Buscaroli A. Bone remodelling after renal transplantation (RT). Adv Exp Med Biol 1984;178:207-16 [Epub 1984/10/23].

[4] Sanchez CP, Salusky IB, Kuijizon BD, et al. Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 1998;53:1358-64 [Epub 1998/05/09].

[5] Parfitt AM. Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab 1982;8:92-112 [Epub 1982/08/01].

[6] Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of bone mineral density 6 months after successful kidney transplantation. Am J Kidney Dis 2004;44:474-56 [Epub 2004/09/24].

[7] Lehmann C, Oth U, Stein G, Steiner T, Wolf G. Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients. Transplant Proc 2007;39:1353-8 [Epub 2007/12/20].
M.Z. Molnar et al. / Transplantation Reviews 28 (2014) 56–62

[43] Coco M, Glucklich D, Faugere MC, et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003;14:2669-75 [Epub 2003/09/30].

[44] Nowacka-Cieciura E, Cieciura T, Baczewska T, et al. Bisphosphonates are effective prophylactic of early bone loss after renal transplantation. Transplant Proc 2006;38:165-7 [Epub 2006/03/01].

[45] Grotz W, Nagel C, Poeschel D, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001;12:1530-7 [Epub 2001/06/26].

[46] Haas M, Leko-Mohr Z, Roschger P, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 2003;63:1130-6 [Epub 2003/03/13].

[47] Torregrosa JV, Fuster D, Gentil MA, et al. Open-label trial: effect of weekly ibandronate immediately after transplantation in kidney recipients. Transplantation 2010;89:1476-81 [Epub 2010/04/16].

[48] Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R. Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney Int 2004;65:304-9 [Epub 2003/12/17].

[49] Palmer SC, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev 2007;3:CD005015 [Epub 2007/07/20].

[50] Coco M, Pullman J, Cohen HW, et al. Effect of risedronate on bone in renal transplant recipients. J Am Soc Nephrol 2012;23:1426-37 [Epub 2012/07/17].

[51] Smerud KT, Dolgos S, Olsen IC, et al. A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation. Am J Transplant 2012;12:3316-25 [Epub 2012/09/06].

[52] Brandenburg VM, Floege J. Transplantation: an end to bone disease after renal transplantation? Nat Rev Nephrol 2013;9:5-6 [Epub 2012/11/14].

[53] Kalantar-Zadeh K, Molnar MZ, Kovesdy CP, Mucsi I, Bunnapradist S. Management of mineral and bone disorders after kidney transplantation: a randomized prospective trial of calcitriol versus alendronate. Transplantation 2003;76:1498-502 [Epub 2003/12/06].

[54] Walsh SB, Altmann P, Patrison J, et al. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. Am J Kidney Dis 2009;53:856-65 [Epub 2009/04/28].

[55] Huang WH, Lee SY, Weng CH, Lai PC. Use of alendronate sodium (Fosamax) to ameliorate osteoporosis in renal transplant patients: a case–control study. Plast Reconstr Surg 2012:7:e48481 [Epub 2012/11/28].

[56] El-Agroudy AE, El-Husseini AA, El-Sayed M, Ghoneim MA. Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol 2003;14:2975-9 [Epub 2003/10/22].

[57] Lopez V, Toledo R, Sola E, et al. Treatment with cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism. Transplant Proc 2010;42:2353-6 [Epub 2010/08/01].

[58] Boca M, Torregrosa JV, Fuster D, Gutierrez-Dalmau A, Oppenheimer F, Campistol JM. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 2008;86:413-7 [Epub 2008/08/14].

[59] Celik D, Benech T, Krestan C, et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant 2008;8:1864-70 [Epub 2008/09/13].

[60] Lertdumrongluk P, Lau WL, Park J, Rhee CM, Kovesdy CP, Kalantar-Zadeh K. Impact of age on survival predictability of bone turnover markers in hemodialysis patients. Nephrol Dial Transplant 2013;28:2335-45 [Epub 2013/05/02].

[61] Li J, Molnar MZ, Zaritsky JJ, et al. Correlates of parathyroid hormone concentration in hemodialysis patients. Nephrol Dial Transplant 2013;28:1516-25 [Epub 2013/01/26].

[62] Lukowsky LR, Molnar MZ, Zaritsky JJ, et al. Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant 2012;27:2899-907 [Epub 2011/12/31].

[63] Kovesdy CP, Kalantar-Zadeh K. Diabetes and secondary hyperparathyroidism in chronic kidney disease. Nephrol Dial Transplant 2011;26:1122-5 [Epub 2011/04/05].

[64] Aysu JC, Negri AL, Kalantar-Zadeh K, Moritz ML. Is chronic hypophosphatemia a novel risk factor for hip fracture in the elderly? Nephrol Dial Transplant 2012;27:3725-31 [Epub 2012/11/02].

[65] Miller JE, Molnar MZ, Kovesdy CP, et al. Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis. Pharmacoeconomics Drug Saf 2012;21:1232-9 [Epub 2012/09/22].

[66] Jefferies J, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation 2003;76:1498-502 [Epub 2003/12/06].

[67] Walsh SB, Altmann P, Patrison J, et al. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. Am J Kidney Dis 2009;53:856-65 [Epub 2009/04/28].

[68] Huang WH, Lee SY, Weng CH, Lai PC. Use of alendronate sodium (Fosamax) to ameliorate osteoporosis in renal transplant patients: a case–control study. Plast Reconstr Surg 2012:7:e48481 [Epub 2012/11/28].

[69] El-Agroudy AE, El-Husseini AA, El-Sayed M, Ghoneim MA. Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol 2003;14:2975-9 [Epub 2003/10/22].

[70] Lertdumrongluk P, Lau WL, Park J, Rhee CM, Kovesdy CP, Kalantar-Zadeh K. Impact of age on survival predictability of bone turnover markers in hemodialysis patients. Nephrol Dial Transplant 2013;28:2335-45 [Epub 2013/05/02].

[71] Lopez V, Toledo R, Sola E, et al. Treatment with cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism. Transplant Proc 2010;42:2353-6 [Epub 2010/11/26].

[72] Copley JB, Germain M, Stern L, et al. Evaluation of cinacalcet HCl treatment after kidney transplantation. Transplant Proc 2010;42:2503-8 [Epub 2010/08/14].

[73] Schwarz A, Merkel S, Leitolf H, Haller H. The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism. Transplantation 2011;91:560-5 [Epub 2010/12/31].